Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy

por Brener, Rafi, Zeitlin, Leonid, Lebenthal, Yael, Brener, Avivit
Publicado 2022

Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia

por Hauser, Robert A., Zeitlin, Leonid, Fisher, Stanley, D’Souza, Richard
Publicado 2020

Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy

por Brener, Avivit, Lebenthal, Yael, Cleper, Roxana, Kapusta, Livia, Zeitlin, Leonid
Publicado 2021

XLH Matters 2022: Insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH)

por Seefried, Lothar, Alzahrani, Ali, Arango Sancho, Pedro, Bacchetta, Justine, Crowley, Rachel, Emma, Francesco, Gibbins, Jonathan, Grandone, Anna, Javaid, Muhammad Kassim, Mindler, Gabriel, Raimann, Adalbert, Rothenbuhler, Anya, Tucker, Ian, Zeitlin, Leonid, Linglart, Agnès
Publicado 2023

IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial

por Hauser, Robert A., Espay, Alberto J., Ellenbogen, Aaron L., Fernandez, Hubert H., Isaacson, Stuart H., LeWitt, Peter A., Ondo, William G., Pahwa, Rajesh, Schwarz, Johannes, Stocchi, Fabrizio, Zeitlin, Leonid, Banisadr, Ghazal, Fisher, Stanley, Visser, Hester, D’Souza, Richard
Publicado 2023